Post reply

The message has the following error or errors that must be corrected before continuing:
Warning: this topic has not been posted in for at least 365 days.
Unless you're sure you want to reply, please consider starting a new topic.
Other options
Verification:
Please leave this box empty:
Type the letters shown in the picture
Listen to the letters / Request another image

Type the letters shown in the picture:
Three blonde, blue-eyed siblings are named Suzy, Jack and Bill.  What color hair does the sister have?:
Please spell spammer backwards:
Shortcuts: ALT+S post or ALT+P preview

Topic summary

Posted by LinksEtc
 - October 01, 2014, 01:22:45 PM
Here's more info

"Omalizumab (Xolair) linked to higher risk of heart attack, mini-stroke (TIA), blood clots - FDA changes the label"

http://allergynotes.blogspot.com/2014/09/omalizumab-xolair-linked-to-higher-risk.html?utm_content=buffer0c6db&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer
Posted by CMdeux
 - October 01, 2014, 09:40:56 AM
Thank you for the update, Links.  I wonder what on earth the mechanism could be?? 
Posted by LinksEtc
 - October 01, 2014, 09:22:55 AM
Tweeted by @MatthewBowdish

"FDA says asthma drug Xolair raises risk of heart, brain problems"
http://www.reuters.com/article/2014/09/26/us-roche-xolair-safety-idUSKCN0HL2EN20140926?feedType=RSS&feedName=healthNews

QuoteThe asthma drug Xolair is associated with a higher risk of heart attack, mini-stroke, chest pain and blood clots in the lungs and veins, among other problems, though the extent of increased risk is unclear, the U.S. Food and Drug Administration said on Friday.


Posted by AdminCM
 - September 09, 2011, 08:06:50 PM
CMdeux Posted: 07/16/09 at 07:52 pm     

--------------------------------------------------------------------------------

http://www.webmd.com/asthma/news/20090716/fda-checking-heart-risk-of-xolair

The summary is pretty much:

Quote

July 16, 2009 -- The FDA is reviewing a possible link between the asthma drug Xolair and an increased risk of heart and cerebrovascular disorders.

Since the FDA investigation is still under way, the agency is not telling doctors to stop prescribing Xolair and is not recommending any changes to the prescribing information for Xolair.

The FDA is looking at interim results of an ongoing study of 5,000 patients with allergic asthma who take Xolair and 2,500 asthmatics who do not take Xolair.

Interim data, submitted by Xolair's manufacturer, Genentech, shows a disproportionate increase in heart and cerebrovascular events in patients treated with Xolair, compared to those who were not given the medication.

Worrisome.   :-/